Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.

Satta A, Grazia G, Caroli F, Frigerio B, Di Nicola M, Raspagliesi F, Mezzanzanica D, Zaffaroni N, Gianni AM, Anichini A, Figini M.

Front Immunol. 2019 Oct 25;10:2514. doi: 10.3389/fimmu.2019.02514. eCollection 2019.

2.

Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.

Dugo M, Devecchi A, De Cecco L, Cecchin E, Mezzanzanica D, Sensi M, Bagnoli M.

Genes (Basel). 2019 Sep 5;10(9). pii: E678. doi: 10.3390/genes10090678.

3.

High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.

Antony F, Deantonio C, Cotella D, Soluri MF, Tarasiuk O, Raspagliesi F, Adorni F, Piazza S, Ciani Y, Santoro C, Macor P, Mezzanzanica D, Sblattero D.

Oncoimmunology. 2019 Jun 4;8(9):e1614856. doi: 10.1080/2162402X.2019.1614856. eCollection 2019.

PMID:
31428516
4.

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.

Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, Mezzanzanica D.

Cells. 2019 Feb 26;8(3). pii: E200. doi: 10.3390/cells8030200.

5.

A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling.

Roggiani F, Riva C, Raspagliesi F, Porta G, Valli R, Taramelli R, Acquati F, Mezzanzanica D, Tomassetti A.

Cancers (Basel). 2019 Feb 22;11(2). pii: E255. doi: 10.3390/cancers11020255.

6.

Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.

Canese R, Palombelli G, Chirico M, Sestili P, Bagnoli M, Canevari S, Mezzanzanica D, Podo F, Iorio E.

NMR Biomed. 2019 Oct;32(10):e4016. doi: 10.1002/nbm.4016. Epub 2018 Oct 30.

PMID:
30375088
7.

One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer.

Rizzo A, Napoli A, Roggiani F, Tomassetti A, Bagnoli M, Mezzanzanica D.

Int J Mol Sci. 2018 Jul 19;19(7). pii: E2092. doi: 10.3390/ijms19072092. Review.

8.

Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.

Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu ML, Nair-Menon J, Bagnoli M, Bortolomai I, Mezzanzanica D, Canevari S, Kourtidis A, Anastasiadis PZ, Tomassetti A.

J Exp Clin Cancer Res. 2018 Jul 11;37(1):146. doi: 10.1186/s13046-018-0796-1.

9.

Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

Satta A, Mezzanzanica D, Caroli F, Frigerio B, Di Nicola M, Kontermann RE, Iacovelli F, Desideri A, Anichini A, Canevari S, Gianni AM, Figini M.

MAbs. 2018 Oct;10(7):1084-1097. doi: 10.1080/19420862.2018.1494105. Epub 2018 Aug 6.

10.

Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model.

Paris L, Podo F, Spadaro F, Abalsamo L, Pisanu ME, Ricci A, Cecchetti S, Altabella L, Buoncervello M, Lozneanu L, Bagnoli M, Ramoni C, Canevari S, Mezzanzanica D, Iorio E, Canese R.

Oncotarget. 2017 Jul 5;8(33):55022-55038. doi: 10.18632/oncotarget.18992. eCollection 2017 Aug 15.

11.

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Erba E, Romano M, Gobbi M, Zucchetti M, Ferrari M, Matteo C, Panini N, Colmegna B, Caratti G, Porcu L, Fruscio R, Perlangeli MV, Mezzanzanica D, Lorusso D, Raspagliesi F, D'Incalci M.

Biochem Pharmacol. 2017 Nov 15;144:52-62. doi: 10.1016/j.bcp.2017.08.001. Epub 2017 Aug 4.

PMID:
28782526
12.

CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.

Dall'Acqua A, Sonego M, Pellizzari I, Pellarin I, Canzonieri V, D'Andrea S, Benevol S, Sorio R, Giorda G, Califano D, Bagnoli M, Militello L, Mezzanzanica D, Chiappetta G, Armenia J, Belletti B, Schiappacassi M, Baldassarre G.

EMBO Mol Med. 2017 Oct;9(10):1415-1433. doi: 10.15252/emmm.201607012.

13.

A miRNA signature assessing ovarian cancer prognosis.

Bagnoli M, Pignata S, Mezzanzanica D.

Oncoscience. 2016 Dec 2;3(11-12):308-310. doi: 10.18632/oncoscience.329. eCollection 2016. No abstract available.

14.

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, Fracasso G, Valdagni R, Mezzanzanica D, Boerman O, Canevari S, Figini M.

Oncotarget. 2017 Feb 14;8(7):10919-10930. doi: 10.18632/oncotarget.14229.

15.

Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism.

Penet MF, Krishnamachary B, Wildes F, Mironchik Y, Mezzanzanica D, Podo F, de Reggi M, Gharib B, Bhujwalla ZM.

Front Oncol. 2016 Nov 16;6:244. eCollection 2016.

16.

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.

Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, Ferrandina G, Franco R, Mezzanzanica D, Sonego M, Zulato E, Zannoni GF, Canzonieri V, Scambia G, Sorio R, Savarese A, Breda E, Scollo P, Ferro A, Tamberi S, Febbraro A, Natale D, Di Maio M, Califano D, Scognamiglio G, Lorusso D, Canevari S, Losito S, Gallo C, Pignata S.

Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056.

17.

Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells.

Roggiani F, Mezzanzanica D, Rea K, Tomassetti A.

Int J Mol Sci. 2016 Aug 23;17(9). pii: E1387. doi: 10.3390/ijms17091387. Review.

18.

In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.

Canese R, Mezzanzanica D, Bagnoli M, Indraccolo S, Canevari S, Podo F, Iorio E.

Front Oncol. 2016 Jun 28;6:164. doi: 10.3389/fonc.2016.00164. eCollection 2016. Review.

19.

Choline Metabolism Alteration: A Focus on Ovarian Cancer.

Bagnoli M, Granata A, Nicoletti R, Krishnamachary B, Bhujwalla ZM, Canese R, Podo F, Canevari S, Iorio E, Mezzanzanica D.

Front Oncol. 2016 Jun 22;6:153. doi: 10.3389/fonc.2016.00153. eCollection 2016. Review.

20.

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.

Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group.

Lancet Oncol. 2016 Aug;17(8):1137-1146. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9.

21.

IL-27 induces the expression of IDO and PD-L1 in human cancer cells.

Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, Petretto A, Fabbi M, Ferrini S.

Oncotarget. 2015 Dec 22;6(41):43267-80. doi: 10.18632/oncotarget.6530.

22.

Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.

Frigerio B, Benigni F, Luison E, Seregni E, Pascali C, Fracasso G, Morlino S, Valdagni R, Mezzanzanica D, Canevari S, Figini M.

Immunol Lett. 2015 Nov;168(1):105-10. doi: 10.1016/j.imlet.2015.09.012. Epub 2015 Sep 25.

PMID:
26404855
23.

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.

Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, Valeri B, Libra M, Barbareschi M, Raspagliesi F, Mezzanzanica D, Canevari S.

Oncotarget. 2015 Apr 30;6(12):9643. No abstract available.

24.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul. Erratum in: J Natl Cancer Inst. 2017 Nov 1;109(11):.

25.

Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma.

Granata A, Nicoletti R, Perego P, Iorio E, Krishnamachary B, Benigni F, Ricci A, Podo F, Bhujwalla ZM, Canevari S, Bagnoli M, Mezzanzanica D.

Oncotarget. 2015 May 10;6(13):11216-30.

26.

Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer.

Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, Mezzanzanica D, Chen KX, Sood AK, Yang D, Zhang W.

Chin J Cancer. 2015 Jan;34(1):28-40. doi: 10.5732/cjc.014.10284. Review.

27.

Ovarian cancer: a molecularly insidious disease.

Mezzanzanica D.

Chin J Cancer. 2015 Jan;34(1):1-3. doi: 10.5732/cjc.014.10301.

28.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD.

Clin Exp Metastasis. 2015 Jan;32(1):29-38. doi: 10.1007/s10585-014-9688-8. Epub 2014 Nov 15.

29.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).

Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8. doi: 10.1097/IGC.0000000000000282. Review.

PMID:
25341581
30.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249. Review.

PMID:
25341579
31.

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.

Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S20-5. doi: 10.1097/IGC.0000000000000289. Review. Erratum in: Int J Gynecol Cancer. 2015 May;25(4):721. Mezzazanica, Delia [corrected to Mezzanzanica, Delia].

PMID:
25341576
32.

MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.

Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W.

J Pathol. 2015 Jan;235(1):25-36. doi: 10.1002/path.4443. Epub 2014 Nov 6.

33.

Epigenetic control of autophagy by microRNAs in ovarian cancer.

Titone R, Morani F, Follo C, Vidoni C, Mezzanzanica D, Isidoro C.

Biomed Res Int. 2014;2014:343542. doi: 10.1155/2014/343542. Epub 2014 Apr 30.

34.
35.

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.

Pisanu ME, Ricci A, Paris L, Surrentino E, Liliac L, Bagnoli M, Canevari S, Mezzanzanica D, Podo F, Iorio E, Canese R.

Br J Cancer. 2014 Feb 4;110(3):625-35. doi: 10.1038/bjc.2013.758. Epub 2013 Dec 12.

36.

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.

Granata A, Nicoletti R, Tinaglia V, De Cecco L, Pisanu ME, Ricci A, Podo F, Canevari S, Iorio E, Bagnoli M, Mezzanzanica D.

Br J Cancer. 2014 Jan 21;110(2):330-40. doi: 10.1038/bjc.2013.729. Epub 2013 Nov 26.

37.

Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma.

Bagnoli M, Beretta GL, Gatti L, Pilotti S, Alberti P, Tarantino E, Barbareschi M, Canevari S, Mezzanzanica D, Perego P.

Biomed Res Int. 2013;2013:143202. doi: 10.1155/2013/143202. Epub 2013 Aug 19.

38.

The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment.

Carbotti G, Barisione G, Orengo AM, Brizzolara A, Airoldi I, Bagnoli M, Pinciroli P, Mezzanzanica D, Centurioni MG, Fabbi M, Ferrini S.

Clin Cancer Res. 2013 Sep 1;19(17):4611-20. doi: 10.1158/1078-0432.CCR-13-0568. Epub 2013 Jul 19.

39.

Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.

Sonego M, Schiappacassi M, Lovisa S, Dall'Acqua A, Bagnoli M, Lovat F, Libra M, D'Andrea S, Canzonieri V, Militello L, Napoli M, Giorda G, Pivetta B, Mezzanzanica D, Barbareschi M, Valeri B, Canevari S, Colombatti A, Belletti B, Del Sal G, Baldassarre G.

EMBO Mol Med. 2013 May;5(5):707-22. doi: 10.1002/emmm.201201504. Epub 2013 Apr 22. Erratum in: EMBO Mol Med. 2014 Feb;6(2):295.

40.

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.

Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M.

Future Oncol. 2013 Apr;9(4):527-39. doi: 10.2217/fon.12.203. Review.

PMID:
23560375
41.

Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.

De Cecco L, Berardi M, Sommariva M, Cataldo A, Canevari S, Mezzanzanica D, Iorio MV, Tagliabue E, Balsari A.

PLoS One. 2013;8(3):e58849. doi: 10.1371/journal.pone.0058849. Epub 2013 Mar 6.

42.

Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.

Carbotti G, Orengo AM, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, Puppo A, Centurioni MG, Bruzzone M, Marroni P, Rossello A, Canevari S, Ferrini S, Fabbi M.

Int J Cancer. 2013 Jun 1;132(11):2597-605. doi: 10.1002/ijc.27948. Epub 2012 Dec 13.

43.

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.

Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, Valeri B, Libra M, Barbareschi M, Raspagliesi F, Mezzanzanica D, Canevari S.

Oncotarget. 2011 Dec;2(12):1265-78. Erratum in: Oncotarget. 2015 Apr 30;6(12):9643.

44.

Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.

Canese R, Pisanu ME, Mezzanzanica D, Ricci A, Paris L, Bagnoli M, Valeri B, Spada M, Venditti M, Cesolini A, Rodomonte A, Giannini M, Canevari S, Podo F, Iorio E.

NMR Biomed. 2012 Apr;25(4):632-42. doi: 10.1002/nbm.1779. Epub 2011 Oct 24.

PMID:
22020805
45.

Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor.

Orengo AM, Fabbi M, Miglietta L, Andreani C, Bruzzone M, Puppo A, Cristoforoni P, Centurioni MG, Gualco M, Salvi S, Boccardo S, Truini M, Piazza T, Canevari S, Mezzanzanica D, Ferrini S.

Int J Cancer. 2011 Sep 1;129(5):1116-25. doi: 10.1002/ijc.25757. Epub 2011 Jan 6.

46.

miRNA control of apoptotic programs: focus on ovarian cancer.

Mezzanzanica D, Canevari S, Cecco LD, Bagnoli M.

Expert Rev Mol Diagn. 2011 Apr;11(3):277-86. doi: 10.1586/erm.11.1. Review.

PMID:
21463237
47.

Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.

Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S, Podo F.

Cancer Res. 2010 Mar 1;70(5):2126-35. doi: 10.1158/0008-5472.CAN-09-3833. Epub 2010 Feb 23.

48.

Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.

Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S.

Int J Biochem Cell Biol. 2010 Aug;42(8):1262-72. doi: 10.1016/j.biocel.2009.12.017. Epub 2009 Dec 24. Review.

PMID:
20035894
49.

Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer.

Bagnoli M, Canevari S, Mezzanzanica D.

Int J Biochem Cell Biol. 2010 Feb;42(2):210-3. doi: 10.1016/j.biocel.2009.11.015. Epub 2009 Nov 22. Review.

PMID:
19932761
50.

c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.

Bagnoli M, Ambrogi F, Pilotti S, Alberti P, Ditto A, Barbareschi M, Galligioni E, Biganzoli E, Canevari S, Mezzanzanica D.

Endocr Relat Cancer. 2009 Jun;16(2):443-53. doi: 10.1677/ERC-08-0218. Epub 2009 Mar 25.

PMID:
19321593

Supplemental Content

Loading ...
Support Center